Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies

Current Opinion in Organ Transplantation

Volumn 17, Issue 3, 2012, Pages 216-224

  Saxena, Varun ^a   Terrault, Norah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Boceprevir; cirrhosis; PEG interferon; ribavirin; telaprevir

Indexed keywords

BOCEPREVIR; CYCLOSPORIN; NORFLOXACIN; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TACROLIMUS; TELAPREVIR;

ANEMIA; ANORECTAL DISEASE; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; PORTAL HYPERTENSION; PREDICTION; PRURITUS; RASH; RECURRENT DISEASE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I; LIVER TRANSPLANTATION; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN;

EID: 84861191809     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283534d64     Document Type: Review

References (38)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6:35-47.
2. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9:331-338. (Pubitemid 36443043)
3. Kim RD, Reed AI, Fujita S, et al. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg 2007; 205:108-123. (Pubitemid 47016954)
4. Ghany MG, Nelson DR, Strader DB,et al. An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the American association for the study of liver diseases. Hepatology 2011; 54:1433-1444.
5. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008; 14 (Suppl. 2):S58-S66.
6. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42:255-262. (Pubitemid 41061075)
7. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39:389-396. (Pubitemid 37070256)
8. Poordad F, Chee GM. Interferon free hepatitis C treatment regimens: the beginning of another era. Curr Gastroenterol Rep 2011; 14:74-77.
9. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-224.
10. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-355. (Pubitemid 34467369)
11. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9:905-915. (Pubitemid 37098838)
12. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50:719-728.
13. Everson GT, Terrault N, Lok AS, et al. Interim analysis of a controlled trial of pre-transplant peginterferon alfa-2B/ribavirin (PEG/RBV) to prevent recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) in the adult-to-adult liver transplantation (A2ALL) study. Hepatology 2009; 50:1690-1692.
14. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46:206-212. (Pubitemid 44959155)
15. Tekin F, Gunsar F, Karasu Z, et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27:1081-1085. (Pubitemid 351614890)
16. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47:484-491. (Pubitemid 47336987)
17. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
18. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
19. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
20. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
21. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
22. Product information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated; 2011.
23. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
24. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
25. Bacon B, Bruno S, Schiff E, et al. Predictors of sustained virologic response among poor interferon responders when boceprevir is added to peginterferon alfa-2b/ribavirin. Hepatology 2011; 54(Suppl.):376A. Abstract 33.
26. Reddy KR, Nunes F, Balart L, et al. An evaluation of neutropenia in the pivotal studies of boceprevir (BOC) plus peginterferon alfa-2b/ribavirin (PR). Hepatology 2011; 54 (Suppl.):814A; Abstract 964.
27. Product information. Victrelis (boceprevir). Whitehouse Station: NMC, Inc.; 2011.
28. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49:274-287.
29. Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6:1586-1599. (Pubitemid 43945798)
30. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15:699-709.
31. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11:1051-1057.
32. Eurich D, Boas-Knoop S, Ruehl M, et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17:289-298.
33. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53:317-324.
34. Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55:322-327.
35. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139:1577-1585; 85 e1-85 e3.
36. Coto-Llerena M, Crespo G, Gonzalez P, et al. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol 2012; 56:355-358.
37. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmaco-kinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-27.
38. Hulskotte EGJ, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and the calcineurin inhibitors cyclos-porine and tacrolimus. Global Antivir J 2011; 7(s1):110.